The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.
Abstract
To assess whether chlorambucil or cyclophosphamide may have a better therapeutic index in patients with idiopathic membranous nephropathy, we compared two regimens based on a 6-mo treatment, alternating every other month methylprednisolone with chlorambucil or methylprednisolone with cyclophosphamide. Patients with biopsy-proven membranous nephropathy and with a nephrotic syndrome were randomized to be given methylprednisolone (1 g intravenously for 3 consecutive days followed by oral methylprednisolone, 0.4 mg/kg per d for 27 d) alternated every other month either with chlorambucil (0.2 mg/kg per d for 30 d) or cyclophosphamide (2.5 mg/kg per d for 30 d). The whole treatment lasted 6 mo; 3 mo with corticosteroids and 3 mo with one cytotoxic drug. Among 87 patients followed for at least 1 yr, 36 of 44 (82%; 95% confidence interval [CI], 67.3 to 91.8%) assigned to methylprednisolone and chlorambucil entered complete or partial remission of the nephrotic syndrome, versus 40 of 43 (93%; 95% CI, 80.9 to 98.5%) assigned to methylprednisolone and cyclophosphamide (P = 0.116). Of patients who attained remission of the nephrotic syndrome, 11 of 36 in the chlorambucil group (30.5%) and 10 of 40 in the cyclophosphamide group (25%) had a relapse of the nephrotic syndrome between 6 and 30 mo. The reciprocal of plasma creatinine improved in the cohort groups followed for 1 yr for both treatment groups (P < 0.01) and remained unchanged when compared with basal values in the cohort groups followed for 2 and 3 yr. Six patients in the chlorambucil group and two in the cyclophosphamide group did not complete the treatment because of side effects. Four patients in the chlorambucil group but none in the cyclophosphamide group suffered from herpes zoster. One patient per group developed cancer. It is concluded that in nephrotic patients with idiopathic membranous nephropathy both treatments may be effective in favoring remission and in preserving renal function for at least 3 yr.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Extension of Box's Results on the Use of the $F$ Distribution in Multivariate Analysis
Geisser, S., & Greenhouse, S. W. (1958) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177706545 · Cited by 1,098
Kinlen, L. J., Sheil, A. G., Peto, J., & Doll, R. (1979) · BMJ · doi:10.1136/bmj.2.6203.1461 · Cited by 593
Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?
Remuzzi, G., & Bertani, T. (1990) · Kidney International · doi:10.1038/ki.1990.217 · Cited by 397
Controlled Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy
Ponticelli, C. E., Zucchelli, P. C., Imbasciati, E., Cagnoli, L., Pozzi, C., Passerini, P., Grassi, C., Limido, D., Pasquali, S., Volpini, T., et al. (1984) · New England Journal of Medicine · doi:10.1056/nejm198404123101503 · Cited by 380
Self-citationThe role of proteinuria in the progression of chronic renal failure
Burton, C., & Harris, K. P. G. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90512-0 · Cited by 316
The increased risk of coronary heart disease associated with nephrotic syndrome
Ordoñez, J. D., Hiatt, R. A., Killebrew, E. J., & Fireman, B. H. (1993) · Kidney International · doi:10.1038/ki.1993.292 · Cited by 296
Martinez, M. (1963) · PubMed · Cited by 296
Neoplasia and glomerular injury
Alpers, C. E., & Cotran, R. S. (1986) · Kidney International · doi:10.1038/ki.1986.209 · Cited by 169
Ponticelli, C., Zucchelli, P., Passerini, P., & Cesana, B. (1992) · New England Journal of Medicine · doi:10.1056/nejm199208273270904 · Cited by 165
Self-citationBaltus, J., Boersma, J. W., Hartman, A. P., et al. (1983) · Annals of the Rheumatic Diseases · doi:10.1136/ard.42.4.368 · Cited by 152
Long-term Outcome of Patients with Membranous Nephropathy After Complete Remission of Proteinuria
Passerini, P., Pasquali, S., Cesana, B. M., et al. (1989) · Nephrology Dialysis Transplantation · doi:10.1093/oxfordjournals.ndt.a091906 · Cited by 36
Self-citation
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up
Dahan, K., Debiec, H., Plaisier, E., Cachanado, M., Rousseau, A., Wakselman, L., Michel, P.-A., Mihout, F., Dussol, B., Matignon, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016040449 · Cited by 439
Hoxha, E., Thiele, I., Zahner, G., Panzer, U., Harendza, S., & Stahl, R. A. K. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013040430 · Cited by 353
Inker, L. A., Heerspink, H. J. L., Tighiouart, H., Levey, A. S., Coresh, J., Gansevoort, R. T., Simon, A. L., Ying, J., Beck, G. J., Wanner, C., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019010007 · Cited by 310
Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study
Fervenza, F. C., Abraham, R. S., Erickson, S. B., Irazabal, M. V., Eirin, A., Specks, U., Nachman, P. H., Bergstralh, E. J., Leung, N., Cosio, F. G., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05080610 · Cited by 299
Metadata
- Authors
- Ponticelli, C., Altieri, P., Scolari, F., Passerini, P., Roccatello, D., Cesana, B., Melis, P., Valzorio, B., Sasdelli, M., Pasquali, S., Pozzi, C., Piccoli, G., Lupo, A., Segagni, S., Antonucci, F., Dugo, M., Minari, M., Scalia, A., Pedrini, L., Pisano, G., Grassi, C., Farina, M., & Bellazzi, R.
- Venue
- Journal of the American Society of Nephrology
- Published
- 1998-03
- Volume
- 9
- Issue
- 3
- Pages
- 444-450
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2115472834
- Cited by
- 389
- References
- 11
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.